Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant depression. PE: How does ...

Drug is the first and only approved monotherapy for refractory major depressive disorder. (HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

Parkside Psychiatric Hospital in Tulsa has an on-site Spravato outpatient clinic that sees over 20 patients per week. According to Parkside, these patients are seen at least twice a week for the ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

Miuzei Basic Starter Kit - It has all consumable component are often used. Compatible with Arduino and Raspberry Pi, it can almost meet all your needs. (Without Microcontroller Board) Breadboard ...

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

However, it may cover Spravato, an FDA-approved drug deriving from ketamine, for treatment-resistant depression. Currently, the Food and Drug Administration (FDA) only approves ketamine for use as ...

According to reports, the FDA approved the Johnson & Johnson drug called Spravato (esketamine) to treat some cases of depression in the 2019 however, this was only allowed as a prescription ...

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.